Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab rezetecan + adebrelimab
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Trastuzumab rezetecan + adebrelimab is a combination therapy consisting of a HER2-targeted antibody-drug conjugate (ADC) and a PD-L1 immune checkpoint inhibitor. Trastuzumab rezetecan (SHR-A1811) is composed of a humanized anti-HER2 monoclonal antibody conjugated to a cytotoxic topoisomerase I inhibitor payload via a cleavable linker. It is designed to deliver potent cytotoxicity directly to HER2-expressing tumor cells. Adebrelimab (SHR-1316) is a humanized monoclonal antibody that targets Programmed cell death 1 ligand 1 (PD-L1), blocking its interaction with PD-1 and B7.1 receptors to restore and enhance anti-tumor T-cell activity. This combination is being evaluated in Phase II clinical trials for the treatment of HER2-positive or HER2-expressing solid tumors, including muscle-invasive bladder cancer (MIBC) and urothelial carcinoma, aiming to leverage the synergistic effects of direct tumor cell killing and immune system activation.
- Other names
- trastuzumab rezetecan + adebelizumab
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)TOP1 (DNA Topoisomerase I)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trastuzumab rezetecan + adebrelimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab rezetecan + adebrelimab.